RxCell has announced a US patent for its induced pluripotent stem cells (iPSCs)-based cell therapy approach, a method of ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

Through TF-based cell fate programming, TFome is designed to yield first-in-class and best-in-class off-the-shelf cell therapy products up to 100 times more rapidly than conventional methods of cell ...

CAR T-cell therapy carried a risk of second primary malignancy (SPM) that was no worse than that of other standard-of-care ...

RxCell Inc. is pleased to announce the issuance of U.S. Patent 11,946,069 entitled "Method for Generating Multiple Cellular ...

GC Therapeutics (GCTx) has launched with its TFome platform, developed by scientists at Harvard and the Wyss Institute, ...

It’s been almost a year since the Food and Drug Administration approved the first genetic treatments for sickle cell disease.

GC Therapeutics has entered gameplay with the mission of unlocking a new generation of cell therapies, uploading with $75 ...

Learn why the FDA has mandated boxed warnings for CAR T-cell therapies, highlighting the risks of secondary malignancies.

The frequency of second primary malignancies (SPMs) arising in cancer survivors following treatment with CAR T-cell therapy was statistically comparable to the frequency of SPMs following other ...